Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 3/20 | 0.32 |
| ▸ | CTSB | P07858 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626687 | 0.98 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1MAPTP2RX7 | |
| SCHEMBL21772022 | 0.94 | CYP4F2 (0.46) | CYP4F2CYP4A11NPSR1P2RX7DPP4 | |
| SCHEMBL25281621 | 0.90 | CYP4F2 (0.44) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL14217137 | 0.82 | OPRM1 (0.36) | CYP4F2CYP4A11NPSR1KMT2ACTSL | |
| SCHEMBL609248 | 0.81 | CYP4F2 (0.49) | CYP4F2CYP4A11NPSR1MAPTP2RX7 | |
| SCHEMBL609232 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1MAPTP2RX7 | |
| SCHEMBL10535707 | 0.79 | CYP4F2 (0.53) | CYP4F2CYP4A11NPSR1MAPTP2RX7 | |
| SCHEMBL15437385 | 0.78 | JAK2 (0.34) | CYP4F2CYP4A11CYP2C19MEN1CYP3A4 | |
| SCHEMBL6632281 | 0.77 | CYP4F2 (0.61) | CYP4F2CYP4A11NPSR1P2RX7DPP4 | |
| SCHEMBL16699602 | 0.76 | SMN1; SMN2 (0.39) | MEN1KMT2AALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| EP-3744718-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019228252-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | 杭州阿诺生物医药科技有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2035379-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2035379-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| EP-2035379-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | CSF1R, CSF3R, CD209 | CYP4F2 3209/4885CYP4A11 3440/4885NPSR1 152/4885 |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | CYP4F2 545/4885CYP4A11 18/4885NPSR1 1093/4885 |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | CSF1R, CSF3R, CD209 | CYP4F2 3209/4885CYP4A11 3440/4885NPSR1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.